# Real-World GLP-1 Weight Loss: Discontinuation, Dose and the Trial Gap | This GLP Real-world GLP-1 weight loss runs below the trial results. The gap comes from 20 to 50 percent stopping in the first year and from lower doses, not from the drug behaving differently. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/glp1-weight-loss-in-ordinary-care Updated: 2026-10-26 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Real-World GLP-1 Weight Loss: Discontinuation, Dose and the Trial Gap Weight loss on GLP-1 drugs in ordinary practice runs below the trial results and approaches them in people who keep taking the drug. Between a fifth and a half stop within the first year. [This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026 Stopping within the first year, real-world · 20% to 50% · The literature reports a range, not a figure. · Weight loss in practice runs below trial results — · and approaches them among the highly adherent. · Doses used are lower than those the trials evaluated. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - Weight reduction in ordinary practice tends to run below what the randomized trials reported. - It approaches trial levels among patients who are highly adherent — the gap is largely about who keeps taking it. - Real-world studies report discontinuation of 20% to 50% within the first year, and doses well below those the trials evaluated. - Gastrointestinal disturbance is frequent, as in the trials. - No clear real-world increase was seen in pancreatitis, pancreatic cancer, thyroid disorders, or depression and self-harm. A trial is a description of what a drug can do under conditions almost nobody experiences: selected patients, free medication, study staff, a protocol for escalation and a schedule for checking in. The question a reader actually has is what it does without any of that. This review is the best available summary, and its answer is a shortfall with a specific cause — one that speaks directly to what is counted in [what the semaglutide trials are worth](https://thisglp.com/research/semaglutide-cochrane-review). ## What the gap is Observed weight reduction in clinical practice tends to be lower than in the randomized trials [\[1\]](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care#ref-1). The interesting part is the qualifier: outcomes approach trial levels when the analysis focuses on highly adherent patients. That locates the gap. It is not that the drug behaves differently outside a trial; it is that people take it differently. Two mechanisms are named — high discontinuation, reported at 20% to 50% within the first year, and the use of much lower doses than the trials evaluated. Ranges, kept as ranges ⛔ “20% to 50%” is what the literature reports, and this page does not collapse it into a single number. A range that wide reflects genuine disagreement between studies about what counts as stopping and over what window, and inventing a point estimate would manufacture a precision the source does not have. This is also a narrative review rather than a meta-analysis. It summarizes a literature instead of pooling it, so nothing here carries a confidence interval. ## One cohort, for scale A single matched study puts a concrete figure inside that range. In a cohort of 18,386 propensity-matched adults starting one of these drugs in ordinary care, follow-up ended in discontinuation for 55.9% of those on tirzepatide against 52.5% of those on semaglutide[\[2\]](https://thisglp.com/research/glp1-weight-loss-in-ordinary-care#ref-2). More than half of each group stopped. That is one study rather than the literature, and it sits at the upper end of the range the review describes. It is included because a range from a fifth to a half is hard to hold, and a single well-matched number gives it a shape. ## The half that is reassuring The same review reports that observational studies in diabetes and obesity populations found frequent gastrointestinal disturbance — consistent with the trials — but no clear increase in the risks that generate the most alarm: pancreatitis, pancreatic cancer, thyroid disorders, or depression and self-harm. That belongs in the same summary as the shortfall. An article reporting only that the drug underperforms outside a trial, while omitting that the feared harms did not materialize outside one either, would be selecting evidence rather than reporting it. The eye-disease question is named as still needing evidence, and we cover the two strands of it in [sudden vision loss](https://thisglp.com/research/does-semaglutide-cause-vision-loss) and [diabetic retinopathy](https://thisglp.com/research/does-semaglutide-make-diabetic-retinopathy-worse). ## What it means for someone buying online The two named causes of the gap are both worse in this market than in ordinary care. Doses are frequently unpublished, so a buyer often cannot tell where on the ladder they are — the silence counted in [who publishes a dose ladder](https://thisglp.com/research/who-publishes-a-glp1-dose-ladder). And discontinuation is driven substantially by cost, which is the whole subject of this category. The practical reading is that trial figures are a ceiling rather than an expectation, and that most of the distance between the ceiling and the floor is decided by whether a person keeps taking the drug at an adequate dose. That is a question about price and about supervision, neither of which most sellers here describe. [knownwell](https://thisglp.com/reviews/knownwell) describes both virtual and in-person obesity care on its [website](https://www.knownwell.co/). Those settings are worth comparing when travel or continuity affects access. They are not interchangeable with this study population, and the service description alone does not establish how long patients remain on treatment. ## Frequently asked Do people lose as much weight as the trials reported? Generally less. Outcomes approach trial levels among highly adherent patients, which locates the gap in how the drug is taken rather than in what it does. How many stop in the first year? Real-world studies report 20% to 50%. That range is what the literature says, and collapsing it to one figure would invent a precision it does not have. Did the feared harms show up in practice? Not clearly. The same review reports no clear real-world increase in pancreatitis, pancreatic cancer, thyroid disorders, or depression and self-harm, alongside frequent gastrointestinal disturbance. ## Sources 1. \[1\] Thomsen RW, et al. (2025). Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies Diabetes, Obesity and Metabolism. [PMID 40196933](https://pubmed.ncbi.nlm.nih.gov/40196933/) 2. \[2\] Rodriguez PJ, et al. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity JAMA Internal Medicine. [PMID 38976257](https://pubmed.ncbi.nlm.nih.gov/38976257/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)